Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders
Thrombosis and Haemostasis · 01.07.2026 · 126 (07) · 673-687
DOI: 10.1055/a-2665-2313 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.07.2026. Verfasst von Yvonne K Jongejan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden Universit…. Hauptthemen laut MEDLINE: von Willebrand Factor, Thrombosis, von Willebrand Diseases, Fibrinolytic Agents. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Von Willebrand factor (VWF) plays an important role in primary hemostasis. Dysregulated plasma VWF levels are implicated in various pathological conditions. Reduced or dysfunctional VWF is associated with bleeding, known as von Willebrand disease. Whereas elevated plasma VWF levels may give rise to an increased risk of developing arterial thrombotic events. In general, antithrombotic strategies in arterial thrombosis primarily focus on inhibiting platelet aggregation; however, treatment failure, antiplatelet drug resistance, and adverse bleeding tendencies underscore the necessity for the development of more efficacious and safer therapeutic modalities. Targeting VWF presents an interesting therapeutic approach as it operates independently of platelet activation pathways for platelet-rich thrombus formation. Over time, several VWF inhibitors have progressed to clinical application for thrombosis management, with ongoing research endeavors exploring novel compounds targeting VWF. This review provides a comprehensive overview of the evolution of VWF-targeting therapeutic agents, elucidating their current developmental stages, clinical indications, and evaluating their respective advantages and limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Yvonne K Jongejan
Zitieren
APA
Jongejan, Y. K., van Vlijmen, B. J. M., & Eikenboom, J. C. J. (2026). Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders. Thrombosis and Haemostasis, 126(07), 673-687. https://doi.org/10.1055/a-2665-2313
Vancouver
Jongejan YK, van Vlijmen BJM, Eikenboom JCJ. Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders. Thrombosis and Haemostasis. 2026;126(07):673-687. doi:10.1055/a-2665-2313
BibTeX
@article{Jongejan2026,
author = {Jongejan, Yvonne K and van Vlijmen, Bart J M and Eikenboom, Jeroen C J},
title = {Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {07},
pages = {673--687},
doi = {10.1055/a-2665-2313}
}
EUVIMED